

20 Dec 2020 |

Quick Listen: Scrip's Five Must-Know Things

by **Ian Haydock**

Join us for an audio catch-up on the past week's major events in the global biopharma industry, as brought to you by Scrip's global team, in this mini podcast version of Five Must-Know Things.

This episode includes the main news from around the biopharma world in the business week ended 18 December 2020.

This week, we look at a big deal in immunology, a story of vaccine success, Japan's vaccine environment, one big pharma firm's challenges and opportunities, and a disappointment in rheumatoid arthritis.

Stories mentioned in this episode:

(Also see "[AZ's Alexion Acquisition Looks Astute Bit Of Business](#)" - Scrip, 13 Dec, 2020.)

(Also see "[Pfizer Rose To The COVID-19 Challenge And The Stars Aligned](#)" - Scrip, 11 Dec, 2020.)

(Also see "[Pharma Power Japan Barely In COVID Vaccines Race. Why?](#)" - Scrip, 16 Dec, 2020.)

(Also see "[AbbVie: Rinvoq And Skyrizi Will Bridge US Humira Sales Erosion Through 2025](#)" - Scrip, 14 Dec, 2020.)

(Also see "[Gilead Gives Up On Galapagos's Filgotinib In RA](#)" - Scrip, 16 Dec, 2020.)

[Click here to explore this interactive content online](#) ✎

These and all Informa Pharma Intelligence podcasts are available on SoundCloud, Apple Podcasts, TuneIn and Google Play and also via smart speakers - just make sure one of these providers is set up as your default for podcasts, and then ask for "Pharma Intelligence podcasts".